Brief: Kinnate Biopharma Inc. Announces Acquisition Of Ownership Stake From Series A Investors Of The China Joint Venture, Kinnjiu Biopharma Inc., And Initiation Of Phase 1 Clinical Trial For Exarafenib (Kin-2787) In People's Republic Of China

Kinnate Biopharma

21/02/2023 22:42

Feb 21 (Reuters) - Kinnate Biopharma Inc  KNTE.O :
    * KINNATE BIOPHARMA INC. ANNOUNCES ACQUISITION OF OWNERSHIP
STAKE
FROM SERIES A INVESTORS OF THE CHINA JOINT VENTURE, KINNJIU
BIOPHARMA INC., AND INITIATION OF PHASE 1 CLINICAL TRIAL FOR
EXARAFENIB (KIN-2787) IN PEOPLE'S REPUBLIC OF CHINA
    * KINNATE BIOPHARMA INC - KINNATE'S CASH RUNWAY STILL
EXPECTED TO
FUND CURRENT OPERATIONS INTO MID-2024
    * KINNATE BIOPHARMA INC - TO RETAIN KINNJIU'S CASH,
INTELLECTUAL
PROPERTY AND OTHER ASSETS, INCLUDING KEY PERSONNEL AND LEGAL
ENTITY STRUCTURE
    * KINNATE BIOPHARMA - KN-8701, PHASE 1 CLINICAL TRIAL WAS
INITIATED IN PEOPLE'S REPUBLIC OF CHINA (PRC), WITH TRIAL SITES
NOW OPEN IN PRC AND TAIWAN

Source text for Eikon:  ID:nGNX4T5sqF 
Further company coverage:  KNTE.O 
 ((Reuters.Briefs@thomsonreuters.com;;))